Anti‐TNF alpha medications and neuropathy

We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the peripheral nervous system Jg. 20; H. 4; S. 397 - 402
Hauptverfasser:	Tsouni, Pinelopi, Bill, Olivier, Truffert, André, Liaudat, Christelle, Ochsner, François, Steck, Andreas J., Kuntzer, Thierry
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Malden, USA Wiley Periodicals, Inc 01.12.2015 Wiley Subscription Services, Inc
Schlagworte:	Adalimumab - adverse effects Adalimumab - therapeutic use Adult Aged anti‐TNF alpha Autoimmune Diseases - drug therapy demyelination Electrodiagnosis Etanercept - adverse effects Etanercept - therapeutic use Female Humans inflammation Infliximab - adverse effects Infliximab - therapeutic use Male Middle Aged Neural Conduction - physiology neuropathies Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - diagnosis Peripheral Nervous System Diseases - physiopathology Rheumatic Diseases - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF neuropathies anti-TNF alpha inflammation demyelination
ISSN:	1085-9489, 1529-8027, 1529-8027
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents.
AbstractList	We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐ TNF ) medications‐induced neuropathies ( ATIN ) in patients with inflammatory disorders. Of 2,017 patients treated with a‐ TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐ TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐ TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐ TNF agents. We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents. We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF) medications-induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a-TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person-years. The median time from a-TNF medication treatment to ATIN was 16.8months (range 2-60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a-TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was "inflammatory", suggesting that it could be due to systemic pro-inflammatory effects of a-TNF agents. We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF) medications-induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a-TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person-years. The median time from a-TNF medication treatment to ATIN was 16.8 months (range 2-60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a-TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was "inflammatory", suggesting that it could be due to systemic pro-inflammatory effects of a-TNF agents.We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF) medications-induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a-TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person-years. The median time from a-TNF medication treatment to ATIN was 16.8 months (range 2-60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a-TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was "inflammatory", suggesting that it could be due to systemic pro-inflammatory effects of a-TNF agents.
Author	Truffert, André Ochsner, François Kuntzer, Thierry Steck, Andreas J. Bill, Olivier Tsouni, Pinelopi Liaudat, Christelle
Author_xml	– sequence: 1 givenname: Pinelopi surname: Tsouni fullname: Tsouni, Pinelopi organization: Lausanne University Hospital (CHUV) – sequence: 2 givenname: Olivier surname: Bill fullname: Bill, Olivier organization: Lausanne University Hospital (CHUV) – sequence: 3 givenname: André surname: Truffert fullname: Truffert, André organization: University Hospital of Geneva (HUG) – sequence: 4 givenname: Christelle surname: Liaudat fullname: Liaudat, Christelle organization: Lausanne University Hospital (CHUV) – sequence: 5 givenname: François surname: Ochsner fullname: Ochsner, François organization: Lausanne University Hospital (CHUV) – sequence: 6 givenname: Andreas J. surname: Steck fullname: Steck, Andreas J. organization: Basel University Hospital – sequence: 7 givenname: Thierry surname: Kuntzer fullname: Kuntzer, Thierry organization: Lausanne University Hospital (CHUV)
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/26309233$$D View this record in MEDLINE/PubMed
BookMark	eNqN0btOwzAUBmALFdELDLwAisQCQml9S-yMVUW5CJWBMkeO46iuUifYiVA3HoFn5EkwbWGoBMIe7OE7Rzr_6YOOqYwC4BTBIfJntDRuiDCi7AD0UISTkEPMOv4PeRQmlCdd0HduCSFiCUqOQBfHBCaYkB64GptGf7y9z2fTQJT1QgQrlWspGl0ZFwiTB0a1tqpFs1gfg8NClE6d7N4BeJ5ezye34cPjzd1k_BBKijALlSwoJJzlMcs5kbGkqsgVThBTkhac05gTyDOSYUYLJRHJIg45zQVjsIiLiAzAxbZvbauXVrkmXWknVVkKo6rWpYhxGCEaU_QPGvtBmZeenu_RZdVa4wfxKmI-Nn-9OtupNvNJpLXVK2HX6XdiHlxugbSVc1YVPwTB9Gsbqd9GutmGt6M9K3WzibaxQpd_VbzqUq1_b53ez562FZ9AiJhd
CitedBy_id	crossref_primary_10_1111_jns_12455 crossref_primary_10_1136_rmdopen_2022_002924 crossref_primary_10_1073_pnas_2114406119 crossref_primary_10_1007_s00415_018_8900_1 crossref_primary_10_1136_dtb_2022_246401_rep crossref_primary_10_1007_s00415_025_13175_0 crossref_primary_10_1093_jnen_nlaf056 crossref_primary_10_1038_s41598_021_03248_1 crossref_primary_10_1136_bcr_2021_246401 crossref_primary_10_3390_life12010118 crossref_primary_10_1016_S0246_0378_25_65746_0 crossref_primary_10_1111_cen3_12694 crossref_primary_10_1590_acb360408 crossref_primary_10_1007_s10067_017_3573_1 crossref_primary_10_1097_MJT_0000000000000835 crossref_primary_10_1186_s12876_021_01780_y crossref_primary_10_3390_diagnostics11111956 crossref_primary_10_1111_ene_14959 crossref_primary_10_1167_iovs_18_24431 crossref_primary_10_1016_j_jns_2024_123204 crossref_primary_10_1177_2040622319851640 crossref_primary_10_1007_s00393_019_0621_z crossref_primary_10_1097_NRL_0000000000000132 crossref_primary_10_1080_14712598_2020_1689953 crossref_primary_10_1111_ejh_14384 crossref_primary_10_1080_14740338_2017_1372421 crossref_primary_10_1111_ene_16285 crossref_primary_10_1136_bcr_2020_236041 crossref_primary_10_1136_jnnp_2019_321663 crossref_primary_10_1007_s40278_016_16880_9
Cites_doi	10.1002/mus.21584 10.1007/s00415-010-5591-7 10.3109/00365521.2013.867358 10.1212/01.WNL.0000158681.29117.8B 10.1002/ibd.23011 10.1007/s10067-013-2419-8 10.1093/rheumatology/kes375 10.1093/brain/awh429 10.1053/j.gastro.2005.06.022 10.1186/ar4582 10.1001/archneurol.2009.11 10.1002/mus.20924 10.1111/j.1529-8027.2010.00245.x 10.1007/s10067-011-1841-z 10.1212/WNL.53.3.457 10.1097/MAJ.0b013e31822b7bb8 10.1093/ckj/sfs067
ContentType	Journal Article
Copyright	2015 Peripheral Nerve Society 2015 Peripheral Nerve Society.
Copyright_xml	– notice: 2015 Peripheral Nerve Society – notice: 2015 Peripheral Nerve Society.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK K9. 7X8
DOI	10.1111/jns.12147
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic
DatabaseTitleList	CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE Neurosciences Abstracts MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Anatomy & Physiology
EISSN	1529-8027
EndPage	402
ExternalDocumentID	3923509181 26309233 10_1111_jns_12147 JNS12147
Genre	article Journal Article
GroupedDBID	--- .3N .GA .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CO8 COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN ENC EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 Q~Q R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION O8X CGR CUY CVF ECM EIF NPM 7TK K9. 7X8
ID	FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53
IEDL.DBID	DRFUL
ISICitedReferencesCount	28
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000368136000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1085-9489 1529-8027
IngestDate	Fri Jul 11 10:50:24 EDT 2025 Sun Nov 09 13:47:53 EST 2025 Sat Nov 29 14:35:46 EST 2025 Thu Apr 03 07:06:00 EDT 2025 Sat Nov 29 05:28:32 EST 2025 Tue Nov 18 22:29:54 EST 2025 Wed Jan 22 16:44:05 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	neuropathies anti-TNF alpha inflammation demyelination
Language	English
License	http://onlinelibrary.wiley.com/termsAndConditions#vor 2015 Peripheral Nerve Society.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
PMID	26309233
PQID	1757529292
PQPubID	1086377
PageCount	6
ParticipantIDs	proquest_miscellaneous_1780514641 proquest_miscellaneous_1760927413 proquest_journals_1757529292 pubmed_primary_26309233 crossref_primary_10_1111_jns_12147 crossref_citationtrail_10_1111_jns_12147 wiley_primary_10_1111_jns_12147_JNS12147
PublicationCentury	2000
PublicationDate	December 2015
PublicationDateYYYYMMDD	2015-12-01
PublicationDate_xml	– month: 12 year: 2015 text: December 2015
PublicationDecade	2010
PublicationPlace	Malden, USA
PublicationPlace_xml	– name: Malden, USA – name: United States – name: La Jolla
PublicationTitle	Journal of the peripheral nervous system
PublicationTitleAlternate	J Peripher Nerv Syst
PublicationYear	2015
Publisher	Wiley Periodicals, Inc Wiley Subscription Services, Inc
Publisher_xml	– name: Wiley Periodicals, Inc – name: Wiley Subscription Services, Inc
References	2013; 19 2013; 18 2009; 66 2010; 15 2010; 257 2005; 128 2013; 52 2005; 129 2014; 16 2014; 49 2008; 37 2005; 64 1999; 53 2012; 5 2010; 41 2011; 342 2012; 31 2014; 33 Bill O (e_1_2_6_4_1) 2013; 18 e_1_2_6_10_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_19_1 e_1_2_6_5_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_13_1 e_1_2_6_14_1 e_1_2_6_3_1 e_1_2_6_11_1 e_1_2_6_2_1 e_1_2_6_12_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1
References_xml	– volume: 128 start-page: 867 year: 2005 end-page: 879 article-title: Peripheral neuropathy in patients with inflammatory bowel disease publication-title: Brain – volume: 257 start-page: 1421 year: 2010 end-page: 1431 article-title: Neurological adverse events associated with anti‐tumor necrosis factor alpha treatment publication-title: J Neurol – volume: 129 start-page: 819 year: 2005 end-page: 826 article-title: Increased risk for demyelinating diseases in patients with inflammatory bowel disease publication-title: Gastroenterology – volume: 31 start-page: 1 year: 2012 end-page: 12 article-title: Beyond the joints: neurological involvement in rheumatoid arthritis publication-title: Clin Rheumatol – volume: 5 start-page: 323 year: 2012 end-page: 326 article-title: Late onset tacrolimus‐induced life‐threatening polyneuropathy in a kidney transplant recipient patient publication-title: Clin Kidney J – volume: 64 start-page: 1468 year: 2005 end-page: 1470 article-title: Neuropathy resembling CIDP in patients receiving tumor necrosis factor‐alpha blockers publication-title: Neurology – volume: 18 start-page: S13 year: 2013 article-title: Immunomodulatory or immunosuppressive‐induced neuropathies publication-title: J Peripher Nerv Syst – volume: 41 start-page: 723 year: 2010 end-page: 727 article-title: Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor‐alpha antagonists publication-title: Muscle Nerve – volume: 19 start-page: 864 year: 2013 end-page: 872 article-title: Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics publication-title: Inflamm Bowel Dis – volume: 53 start-page: 457 year: 1999 end-page: 465 article-title: TNF neutralization in MS: results of a randomized, placebo‐controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group publication-title: Neurology – volume: 49 start-page: 173 year: 2014 end-page: 176 article-title: Crohn's disease: is there a place for neurological screening? publication-title: Scand J Gastroenterol – volume: 37 start-page: 281 year: 2008 end-page: 292 article-title: Tumor necrosis factor‐alpha antagonists and neuropathy publication-title: Muscle Nerve – volume: 342 start-page: 352 year: 2011 end-page: 355 article-title: Neurological deficits during treatment with tumor necrosis factor‐alpha antagonists publication-title: Am J Med Sci – volume: 52 start-page: 868 year: 2013 end-page: 874 article-title: Pattern of demyelination occurring during anti‐TNF‐alpha therapy: a French national survey publication-title: Rheumatology – volume: 33 start-page: 719 year: 2014 end-page: 723 article-title: Demyelinizing neurological disease after treatment with tumor necrosis factor alpha‐inhibiting agents in a rheumatological outpatient clinic: description of six cases publication-title: Clin Rheumatol – volume: 16 start-page: R125 year: 2014 article-title: Neurological adverse events in patients receiving anti‐TNF therapy: a prospective imaging and electrophysiological study publication-title: Arthritis Res Ther – volume: 66 start-page: 490 year: 2009 end-page: 497 article-title: Long‐term course of demyelinating neuropathies occurring during tumor necrosis factor‐alpha‐blocker therapy publication-title: Arch Neurol – volume: 15 start-page: 1 year: 2010 end-page: 9 article-title: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society‐‐First Revision publication-title: J Peripher Nerv Syst – ident: e_1_2_6_2_1 doi: 10.1002/mus.21584 – ident: e_1_2_6_19_1 doi: 10.1007/s00415-010-5591-7 – ident: e_1_2_6_16_1 doi: 10.3109/00365521.2013.867358 – ident: e_1_2_6_13_1 doi: 10.1212/01.WNL.0000158681.29117.8B – ident: e_1_2_6_15_1 doi: 10.1002/ibd.23011 – ident: e_1_2_6_18_1 doi: 10.1007/s10067-013-2419-8 – ident: e_1_2_6_14_1 doi: 10.1093/rheumatology/kes375 – ident: e_1_2_6_6_1 doi: 10.1093/brain/awh429 – ident: e_1_2_6_7_1 doi: 10.1053/j.gastro.2005.06.022 – ident: e_1_2_6_8_1 doi: 10.1186/ar4582 – ident: e_1_2_6_9_1 doi: 10.1001/archneurol.2009.11 – ident: e_1_2_6_17_1 doi: 10.1002/mus.20924 – ident: e_1_2_6_5_1 doi: 10.1111/j.1529-8027.2010.00245.x – ident: e_1_2_6_11_1 doi: 10.1007/s10067-011-1841-z – volume: 18 start-page: S13 year: 2013 ident: e_1_2_6_4_1 article-title: Immunomodulatory or immunosuppressive‐induced neuropathies publication-title: J Peripher Nerv Syst – ident: e_1_2_6_3_1 doi: 10.1212/WNL.53.3.457 – ident: e_1_2_6_10_1 doi: 10.1097/MAJ.0b013e31822b7bb8 – ident: e_1_2_6_12_1 doi: 10.1093/ckj/sfs067
SSID	ssj0017919
Score	2.2313888
Snippet	We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF)... We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐ TNF )... We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti-tumor necrosis factor alpha (a-TNF)...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	397
SubjectTerms	Adalimumab - adverse effects Adalimumab - therapeutic use Adult Aged anti‐TNF alpha Autoimmune Diseases - drug therapy demyelination Electrodiagnosis Etanercept - adverse effects Etanercept - therapeutic use Female Humans inflammation Infliximab - adverse effects Infliximab - therapeutic use Male Middle Aged Neural Conduction - physiology neuropathies Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - diagnosis Peripheral Nervous System Diseases - physiopathology Rheumatic Diseases - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF
Title	Anti‐TNF alpha medications and neuropathy
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjns.12147 https://www.ncbi.nlm.nih.gov/pubmed/26309233 https://www.proquest.com/docview/1757529292 https://www.proquest.com/docview/1760927413 https://www.proquest.com/docview/1780514641
Volume	20
WOSCitedRecordID	wos000368136000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1529-8027 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017919 issn: 1085-9489 databaseCode: DRFUL dateStart: 20000101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8RADA66ivjifazHUkXEl0LbOYtPoi4iuogH7FtppzMgaJXdVfDNn-Bv9JeYmXaLiweCb4VJYJgkTTLJfAHY4YaEHD2bn3NCMUGhuS8xK_ADbfMRzWhGjBs2ITod2e3GF2OwP3wLU-JD1Bdu1jLc_9oaeJr1Pxs5CiW0U3bGYSJCvWUNmDi6bN-c1UUEEbu5Hq6_PqYyroCFXCPPkHnUHX2JMUdDVudz2rP_2u0czFShpndQ6sY8jOliARYPCkyz71-8Xc81f7pb9QWYOq9q7Itg8QRu31_frjttz73E9Vz9vbzZ89Ii9xwGph1l_LIEN-3j68MTvxqp4CsaRsLXylBbsM65yCVRXFFtch2hdLSiRmIwIkkgM5Jhsmq0CknGZCBpngoRGG4YWYZG8VDoVfBSHRoWZDJXTNjiX8aCNEI2ZjL0hlI2YW94somq8Mbt2Iu7pM47in7izqQJ2zXpYwmy8R3RxlA8SWVnuCIw3IwwxIuasFUvo4XYskda6IcnS8OD2KL0kN9opAWC5zRswkop-nonESfIT5B7z0n45y0mp50r97H2d9J1mMYYjJUdMhvQGPSe9CZMqufBbb_XgnHRla1KsT8Aqaj3HA
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEB68UF881ms9q4jsS6Ft0jQFX0RdPHaL6Aq-lTZNYEG74q6Cb_4Ef6O_xEnaLYoHgm-FzEDIzHSu5BuAXaaIy9Cz2RkjFBMUmtkcswLbkTofkT5NiTLDJoIo4jc34cUI7A_fwhT4EFXBTVuG-V9rA9cF6Y9WjlJx9ZidURinqEao3-NHl83rVtVFCEIz2MNcsA8pD0tkIXOTZ8j82R99CTI_x6zG6TRn_7fdOZgpg03roNCOeRiReQ0WDnJMtO-erT3LXP80dfUaTLbLLvsCaESB7tvLaydqWuYtrmU68EVtz0ryzDIomHqY8fMiXDePO4cndjlUwRbU9QJbCkV1yzpjQcaJYIJKlUkP5SMFVRzDEU4cnpIU01UlhUtSnzucZkkQOIopnyzBWN7L5QpYiXSV76Q8E36g23-p7yQesvkqRX_IeR0aw6ONRYk4rgdf3MZV5pH3Y3MmddipSO8LmI3viNaH8olLS8OVAANOD4M8rw7b1TLaiG58JLnsPWoa5oQap4f8RsM1FDyjbh2WC9lXO_EYQX6C3A0j4p-3GJ9FV-Zj9e-kWzB10mm34tZpdL4G0xiR-cV9mXUYGzw8yg2YEE-Dbv9hs9Tvd6l7-iQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8VADA76FPHivjzXKiJeCm1nOp2CF1GLaxEX8FbaWeCBVnlPBW_-BH-jv8TMtK8oLgjeCpNAmEyaZJL5ArDBNPEZejZXMkIxQaHS5ZgVuJ4y-YgKaUG0HTYRpSm_vo7PBmC7_xamwodoLtyMZdj_tTFwdS_1RytHrfhmzM4gDFEzRKYFQ3vnydVJU0WIYjvYwzbYx5THNbKQ7eTpM3_2R1-CzM8xq3U6yfj_xJ2AsTrYdHaq0zEJA6qcgumdEhPt22dn07Htn_ZefQpGTusq-zQYRIHO28vrZZo49i2uYyvw1d2ek5fSsSiYZpjx8wxcJfuXuwduPVTBFdQPIlcJTU3JWrJIciKYoEpLFaB-lKCaYzjCiccLUmC6qpXwSRFyj1OZR5GnmQ7JLLTKu1LNg5MrX4dewaUII1P-K0IvD5At1AX6Q87bsNXf2kzUiONm8MVN1mQeZS-ze9KG9Yb0voLZ-I5oqa-frLY0XIkw4AwwyAvasNYso42YwkdeqrtHQ8O82OD0kN9ouIGCZ9Rvw1yl-0aSgBHkJ8i9ZVX8s4jZUXphPxb-TroKI2d7SXZymB4vwigGZGHVLrMErYfuo1qGYfH00Ol1V-rj_Q479Pmf
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti%E2%80%90TNF+alpha+medications+and+neuropathy&rft.jtitle=Journal+of+the+peripheral+nervous+system&rft.au=Tsouni%2C+Pinelopi&rft.au=Bill%2C+Olivier&rft.au=Truffert%2C+Andr%C3%A9&rft.au=Liaudat%2C+Christelle&rft.date=2015-12-01&rft.issn=1085-9489&rft.eissn=1529-8027&rft.volume=20&rft.issue=4&rft.spage=397&rft.epage=402&rft_id=info:doi/10.1111%2Fjns.12147&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_jns_12147
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1085-9489&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1085-9489&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1085-9489&client=summon